We welcome interest from investors and are happy to provide more information on Elypta’s plans for development and commercialisation on request.

The academic research & development activities leading to the founding of Elypta was conducted at the Systems and Synthetic Biology division, Department of Biology and Biological Engineering at Chalmers University of Technology, Gothenburg, Sweden.

R&D and commercialisation activities are in part financed by the Horizon 2020 programme of the European Union, Region Västra Götaland, SWElife, a strategic innovation programme funded by the Swedish Government via the Swedish innovation agency, Vinnova, and EIT Health, an entity supported by EIT, a body of the European Union.

Chalmers Ventures is among Elypta’s early investors.


Investor jar.jpg